Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up C Agusti, A Xaubet, J Roca, A G N Agusti, R Rodriguez-Roisin Abstract Background Interstitial pulmonary fibrosis is a disease with a highly variable clinical course. To ascertain if an inadequate selection of patients might explain part of this variability, two different groups of patients with interstitial pulmonary fibrosis, those with the "lone" form of the disease (LIPF) and those with associated collagen vascular disorders (AIPF), were studied separately. Methods Twenty consecutive patients (nine with LIPF and 11 with AIPF) were included. Their clinical and radiographic findings and results of pulmonary function tests, gallium-67 lung scanning, and cellular analysis of bronchoalveolar lavage fluid were compared at diagnosis. Moreover, the evolution of LIPF and AIPF was contrasted after a follow up of two years, both groups having received a similar treatment We have compared clinical and radiographic findings, lung function, and indices of inflammation (gallium-67 lung scanning, and bronchoalveolar lavage cell counts) at diagnosis in patients with LIPF and with AIPF. Similarly, we have noted any changes over a follow up period of two years.
Patients and methods

PATIENTS WITH LIPF
We studied nine consecutive patients. M-male; F-female; Ex-ex-smoker; LHI-lung hepatic index; Sc-scleroderma; RA-rheumatoid arthritis; bronchoalveolar lavage fluid; NA-not available; L-lymphocytes; N-neutrophils; E-eosinophils.
during the follow up period. The entire study was performed as part of the full diagnostic assessment and outpatient care protocol for interstitial lung disease in our centre. Accordingly, all patients were informed of the characteristics and nature of the procedures performed and all gave consent. All examinations took place when the diagnosis of pulmonary fibrosis was first made. None of them had received previous steroid or immunosuppressive treatment.
CLINICAL AND RADIOGRAPHIC ASSESSMENT
An extended Epidemiological Standardisation Project questionnaire was administered to each patient and a full physical examination was carried out. 20 The severity of dyspnoea and the presence of inspiratory crackles were graded according to criteria reported previously.2' Posteroanterior chest radiographs were evaluated according to the International Labour Office/International Union Against Cancer 1980 classification of pneumoconioses by two blinded and independent readers. The final assessment of each film represented the median interpretation of these two readers.2'
PULMONARY FUNCTION TESTS
In each patient, forced spirometric indices, slow vital capacity (HP 47804A Pulmonary System Desk; Hewlett-Packard, Waltham, MA), thoracic gas volume and airway resistance (Body test; E Jaeger, Wurzburg, Germany), and the single breath carbon monoxide transfer factor (Resparamater Model A; PK Morgan Ltd, Chatham, Kent, UK) were measured. The reference values used in this Dms-dermatomyositis; BALstudy were those of our own laboratory. 202223 All but one patient had arterial blood gases measured at rest while breathing air (IL 1302 Instrument Laboratories, Milano, Italy). The alveolar-arterial Po2 difference (A-aDo2) was calculated by using the standard formula with a respiratory exchange ratio (R) of 0 8.
GALLIUM LUNG SCAN
Gallium lung scans were performed with a gamma camera (4/15 Picker) connected on line to a digital computer, 48 hours after the intravenous administration of 2 to 5 mCi of gallium citrate. The quantified lung activity was then compared with hepatic activity and a lung hepatic index obtained. An increase of pulmonary parenchymal uptake of gallium-67 was considered when the lung hepatic index was higher than 0.25.24 BRONCHOALVEOLAR LAVAGE Bronchoalveolar lavage was performed by flexible fibreoptic bronchoscopy with a total volume of 150 ml of 0 9% sterile saline in three 50 ml aliquots as previously described.2' The normal differential count in our laboratory is: macrophages 94 (2)%, lymphocytes 4-8 (3)%, neutrophils 1 3 (0-8)%, eosinophils 0-1 (0-2)%, and mast cells 0 (0)%.21
TREATMENT AND FOLLOW UP At the time of the diagnosis, none of the patients had received steroids; thereafter, they received prednisone (1 mg/kg/day; maximum, 100 mg/day) for four to six weeks. Treatment was continued on the lowest dose of prednisone (range 5-30 mg/day) to maintain both maximal (0-47 (0-1) ), but the was the same in six patients and worse in only one; and the severity of radiographic shadowing was unchanged in five patients and worse in two. By contrast, most of the indices of lung function showed a substantial deterioration after two years of evolution. There was a significant decrease in FVC (p < 0 002), FEVy (p < 0-001), TLC (p < 0-04), transfer factor (p < 0-03), and Pao2 (p < 0 04).
FOLLOW UP OF PATIENTS WITH AIPF
As in patients with LIPF, clinical and radiographic findings for patients with AIPF remained virtually unchanged after two years. Individually the degree of dyspnoea was stable in eight patients and worse in two; the severity of crackles was unchanged in seven and worse in one. Finally, no patient showed a change in radiographic appearance of the lungs. Similarly, the evolution of indices of lung function after two years of follow up in patients with AIPF remained unchanged. Figure 1 shows the changes from entry to the study for the most representative lung function tests for the two groups of patients.
COMPARISON BETWEEN PATIENTS WITH LIPF AND AIPF
We compared the evolution of the indices of lung function (% change from entry to the study) after two years. Patients with LIPF showed a significant decrease in FVC (p < 0-01), FEV, (p < 0-005), and Pao2
(p < 0 01) (figure 2).
Discussion
The present study confirms that interstitial pulmonary fibrosis is a disorder with a variable clinical course. Whereas patients with LIPF seem to deteriorate, those with AIPF change less. This could partly explain both the variability and unpredictibility of the natural history of interstitial pulmonary fibrosis seen in studies in which these two groups of patients have been mixed together.4"'"25 Although it could be argued that only a few patients evaluated had confirmation by biopsy, all fulfilled the common, well established, clinical criteria for the diagnosis of pulmonary fibrosis applied in many ofthe larger series reported.248 In the present study, patients with LIPF complained more often of dyspnoea and had a worse radiographic score at diagnosis. Although these findings initially suggest that the patients with LIPF had more advanced disease, several comments need to be made. Firstly, dyspnoea during physical effort may be easily underestimated in patients with AIPF because of limited mobility.26 Secondly, there were no differences in the severity of either dyspnoea or crackles between the two groups. Thirdly, it is accepted that pulmonary function indices are more sensitive and have a better correlation with the underlying lung pathology than pulmonary symptoms and chest radiographs.2" In this regard, our two groups of patients showed similar lung function at diagnosis, suggesting that they were at a comparable stage of their disease. Patients with either diagnosis showed a mild to moderate reduction in lung volumes with low transfer factor and mild hypoxaemia. Two years later, lung function in patients with LIPF had significantly deteriorated, whereas no evidence of disease progression was found in patients with AIPF, both groups having received comparable steroid treatment. In patients with LIPF, lung volumes decreased and there was further deterioration in gas exchange, suggesting a loss of alveolar units and reduced lung compliance. This would cause more ventilation-perfusion mismatch and also more diffusion limitation for oxygen.28 The lack of a significant change in A-aDO2 in the presence of a further decrease in Pao2 may be explained by the errors inherent in its calculation (the respiratory exchange ratio R was assumed not to have altered, but PaCo2 tended to increase over the two years). On the other hand, patients with AIPF remained functionally stable after two years. It is accepted that the prognosis of patients with scleroderma and rheumatoid arthritis depends on the extent of visceral involvement.26 Several authors have shown that, although both acute and subacute progression may occur, the pulmonary interstitial process is not always progressive.26293" Indeed, three retrospective studies have shown that patients with scleroderma had no greater deterioration in vital capacity or transfer factor than that expected in healthy subjects over a three to five year follow up period. 3'133 Similarly, although controlled studies are lacking, patients with pulmonary fibrosis and rheumatoid arthritis may follow an indolent course even with radiographic evidence of disease. 26 3' Interestingly, in the present study one of the patients with AIPF with dermatomyositis showed a substantial clinical, radiographic, and functional improvement after two years of steroid treatment (patient 20). By contrast with patients with scleroderma and rheumatoid arthritis, patients with dermatomyositis can respond well to steroid treatment. 35 36 Although our results did not differ when the two patients with dermatomyositis were excluded, their different response to steroids suggests that the clinical course could also be different, depending on the specific type of underlying collagen vascular disorder.
The poorer outcome of patients with LIPF might be predicted by three findings at diagnosis. Firstly, by contrast with patients with AIPF, they had finger clubbing, a sign that has been associated with pulmonary angiogenesis and rapid progression of the disease."7 Secondly, patients with LIPF had a more substantial uptake of gallium-67 by the lung parenchyma (although the difference was not significant), suggesting that they might have more severe interstitial inflammation.8 Thirdly, these patients showed a significant increase in eosinophils in bronchoalveolar lavage fluid compared with those with AIPF. Although the presence of increased numbers of eosinophils in bronchoalveolar lavage fluid from patients with AIPF is a well known finding,'4 38 
